A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
Bilal A. Siddiqui(The University of Texas MD Anderson Cancer Center), Elizabeth Miller(Unknown), Sabina Sandigursky(Regeneron (United States)), Israel Lowy(Bristol-Myers Squibb (Germany)), Matthew Ingham(Columbia University), Pradeep Thanigaimani(Regeneron (United States)), Edward P. Gelmann(University of Arizona), Kai Tsao(Icahn School of Medicine at Mount Sinai), Joseph W. Kim(National Cancer Institute), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Benedito A. Carneiro(Brown University), Mark N. Stein(Cornell University), David R. Wise, Fang Fang(Jinshan Hospital of Fudan University), Xīn Gào(Qingdao University), Jingsong Zhang(Moffitt Cancer Center), William Kevin Kelly(Thomas Jefferson University), Michael D. Kinnaman(Regeneron (United States)), Przemyslaw Twardowski(Saint John's Health Center), Frank Seebach(Regeneron (United States))
Cited by 4
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k